Maintenance IV Ketamine Therapy in the Fibromyalgia Patient: A Case Report
Introduction
Fibromyalgia is a complex disorder characterized by distributed and persistent pain often associated with fatigue and depression. The underlying causal agents of this dysfunction are not clear. Ketamine has been used to treat chronic pain in a variety of pain syndromes, including fibromyalgia, but the dosing protocols used are neither standardized nor consistent across cases. The current case presents an opportunity to contribute to a progression towards a consensus on ketamine dosing for fibromyalgia.
Case Presentation
A 60-year-old female presented with indications of fibromyalgia and was administered a 9-session IV ketamine treatment for pain. The initial dosing was 50 mg, with a concentration of 1.0 mg/ml at an infusion rate of 0.8 mg/kg/hr. This was increased to 200 mg and eventually to 240 mg, maintaining a ketamine concentration 4.0–4.8 mg/ml at an infusion rate of 1.5 mg/kg/hr.
Management and Outcomes
Following the first 9-session therapy, the patient reported >50% pain relief from pre-infusion levels and was placed on a maintenance regimen in perpetuity. This regimen involves two monthly IV ketamine infusions, one day apart for two hours at a maintenance rate of 4.8 mg/kg/hr.
Conclusion
Ketamine by IV is an effective option for pain management in patients with fibromyalgia. Compared to previous case studies, it is recommended that increased total dose, frequent administration, and longer duration of infusions all may be necessary for ketamine to maximize its beneficial effects.
1. Bair MJ, Krebs EE. Fibromyalgia. Ann Intern Med.2020;172(5):ITC33-48. doi:10.7326/aitc202003030
2. Clauw DJ. Fibromyalgia: A Clinical Review. JAMA.2014;311(15):1547-1555. doi:10.1001/jama.2014.3266
3. Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456-466. doi:10.1097/aap.0000000000000806
4. Rosenbaum SB, Gupta V, Patel P, Palacios JL. Ketamine. In: StatPearls. StatPearls Publishing;2023.
5. Orhurhu VJ, Roberts JS, Ly N, Cohen SP. Ketamine in acute and chronic pain management. In: StatPearls. StatPearls Publishing;2023.
6. Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med.2018;43(5):521-546. doi:10.1097/aa p.0000000000000808
7. Siracusa R, Di Paola R, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, mechanisms, diagnosis and treatment options update. International Journal of Molecular Sciences.2021;22(8):3891. doi:10.3390/ijms 22083891
8. Corwell BN, Motov SM, Davis NL, Kim HK. Novel uses of ketamine in the Emergency Department. Expert Opinion on Drug Safety.2022;21(8):1009-1025. doi:10.1080/14740338.2022.2100883
9. Barreveld AM, Correll DJ, Liu X, et al. Ketamine decreases postoperative pain scores in patients taking opioids for chronic pain: Results of a prospective, randomized, double-blind study. Pain Med.2013;14(6):925-934. doi:10.1111/pme.12086
10. Eichenberger U, Neff F, Sveticic G, et al. Chronic phantom limb pain: The effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesthesia & Analgesia. 2008;106(4):1265-1273. doi:10.1213/ane.0b013e3181685014
11. Graven-Nielsen T, Kendall SA, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain.2000;85(3):483-491. doi:10.1016/s0304-3959(99)00308-5
12. Kugler NW, Carver TW, Juul J, et al. Ketamine infusion for pain control in elderly patients with multiple rib fractures: Results of a randomized controlled trial. J Trauma Acute Care Surg.2019;87(5):1181-1188. doi:10.1097/ta.0000000000002479
13. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A. Ketamine for the treatment of chronic non-cancer pain. Expert Opinion on Pharmacotherapy.2010;11(14):2417-2429. doi:10.1517/14656566.2010.515978
14. Persson J, Hasselstrom J, Wiklund B, Heller A, Svensson JO, Gustafsson LL. The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesiol Scand.1998;42(7):750-758. doi:10.1111/j.1399-6576.1998.tb 05317.x
15. Pickering G, Pereira B, Morel V, et al. Ketamine and magnesium for refractory neuropathic pain: A randomized, double-blind, crossover Trial. Anesthesiology.2020;133(1):154-164. doi:10.1097/al n.0000000000003345
16. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of Complex Regional Pain Syndrome: A double-blind placebo controlled study. Pain.2009;147(1-3):107-115. doi:10.1016/j.pain.2009.08.015
17. Sigtermans MJ, van Hilten JJ, Bauer MCR, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain.2009;145(3):304-311. doi:10.1016/j.pain.2009.06.023
18. Sorensen J, Bengtssson A, Ahlner J, Henriksson KG, Ekselius L, Bengtsson M. Fibromyalgia--are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol. 1997;24(8):1615-1621.